The advantages, pitfalls and limitations of guideline‐directed medical therapy in patients with valvular heart disease
暂无分享,去创建一个
[1] P. Ponikowski,et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. , 2020, The New England journal of medicine.
[2] Y. Bossé,et al. Genetic and In Vitro Inhibition of PCSK9 and Calcific Aortic Valve Stenosis , 2020, JACC. Basic to translational science.
[3] John E A Blair,et al. Impact of Loop Diuretic Use on Outcomes Following Transcatheter Aortic Valve Implantation. , 2020, The American journal of cardiology.
[4] R. Guddeti,et al. Lipoprotein(a) and calcific aortic valve stenosis: A systematic review. , 2020, Progress in cardiovascular diseases.
[5] P. Ponikowski,et al. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. , 2020, The New England journal of medicine.
[6] G. Mancia,et al. Hypertension in aortic stenosis: a focused review and recommendations for clinical practice. , 2020, Journal of hypertension.
[7] Kiyoshi Yoshida,et al. Subtypes of Atrial Functional Mitral Regurgitation: Imaging Insights Into Their Mechanisms and Therapeutic Implications. , 2020, JACC. Cardiovascular imaging.
[8] B. Prendergast,et al. Secondary mitral regurgitation: pathophysiology, proportionality and prognosis , 2020, Heart.
[9] J. Chambers. Specialist valve clinic: why, who and how? , 2019, Heart.
[10] S. Stewart,et al. Poor Long-term Survival in Patients with Moderate Aortic Stenosis. , 2019, Journal of the American College of Cardiology.
[11] G. Keren,et al. Tricuspid regurgitation and long-term clinical outcomes. , 2019, European heart journal cardiovascular Imaging.
[12] Akshay S. Desai,et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. , 2019, The New England journal of medicine.
[13] Wei-Chieh Lee,et al. Ivabradine for the Treatment of Acute Mitral-Regurgitation-Related Decompensated Heart Failure , 2019, Cardiology.
[14] S. Kapadia,et al. Outcomes of patients with severe tricuspid regurgitation and congestive heart failure , 2019, Heart.
[15] M. Packer,et al. Neurohormonal and Transcatheter Repair Strategies for Proportionate and Disproportionate Functional Mitral Regurgitation in Heart Failure. , 2019, JACC. Heart failure.
[16] Jeroen J. Bax,et al. Aortic Stenosis and Heart Failure: Disease Ascertainment and Statistical Considerations for Clinical Trials , 2019, Cardiac failure review.
[17] S. Yun,et al. Angiotensin Receptor Neprilysin Inhibitor for Functional Mitral Regurgitation: PRIME Study , 2019, Circulation.
[18] M. Enriquez-Sarano,et al. Burden of Tricuspid Regurgitation in Patients Diagnosed in the Community Setting. , 2019, JACC. Cardiovascular imaging.
[19] S. Kaveh,et al. Comparative efficacy of ivabradine versus beta-blockers in patients with mitral stenosis in sinus rhythm: systematic review and meta-analysis , 2019, International Journal of Clinical Pharmacy.
[20] C. Yancy,et al. Medication dosing for heart failure with reduced ejection fraction — opportunities and challenges , 2018, European journal of heart failure.
[21] D. Maucort-Boulch,et al. Percutaneous Repair or Medical Treatment for Secondary Mitral Regurgitation , 2018, The New England journal of medicine.
[22] B. Prendergast. Faculty of 1000 evaluation for 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2018 .
[23] P. Pellikka,et al. Reduced Left Ventricular Ejection Fraction in Patients With Aortic Stenosis. , 2018, Journal of the American College of Cardiology.
[24] W. Aronow. Hypertension, aortic stenosis, and aortic regurgitation. , 2018, Annals of translational medicine.
[25] P. Okin,et al. Antihypertensive Treatment With β‐Blockade in Patients With Asymptomatic Aortic Stenosis and Association With Cardiovascular Events , 2017, Journal of the American Heart Association.
[26] A. Sannino,et al. Survival and Cardiovascular Outcomes of Patients With Secondary Mitral Regurgitation: A Systematic Review and Meta-analysis , 2017, JAMA cardiology.
[27] J. Sörensen,et al. Metoprolol Reduces Hemodynamic and Metabolic Overload in Asymptomatic Aortic Valve Stenosis Patients: A Randomized Trial , 2017, Circulation. Cardiovascular imaging.
[28] M. Claeys,et al. Evolution of Functional Mitral Regurgitation and Prognosis in Medically Managed Heart Failure Patients With Reduced Ejection Fraction. , 2017, JACC. Heart failure.
[29] J. Mascherbauer,et al. Refining the prognostic impact of functional mitral regurgitation in chronic heart failure , 2017, European heart journal.
[30] P. Ponikowski,et al. Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study , 2017, European heart journal.
[31] E. Frangou,et al. Large-scale community echocardiographic screening reveals a major burden of undiagnosed valvular heart disease in older people: the OxVALVE Population Cohort Study. , 2016, European heart journal.
[32] M. Leon,et al. Medical Treatment of Aortic Stenosis , 2016, Circulation.
[33] D. Mele,et al. Role of cardiac dyssynchrony and resynchronization therapy in functional mitral regurgitation. , 2016, European heart journal cardiovascular Imaging.
[34] R. Nicoll,et al. The effect of statins on valve function and calcification in aortic stenosis: A meta-analysis. , 2016, Atherosclerosis.
[35] S. Urheim,et al. Controlled release metoprolol for aortic regurgitation: a randomised clinical trial , 2015, Heart.
[36] J. Afilalo,et al. Complications Associated With Nitrate Use in Patients Presenting With Acute Pulmonary Edema and Concomitant Moderate or Severe Aortic Stenosis. , 2015, Annals of emergency medicine.
[37] I. Burwash,et al. Low Gradient Aortic Stenosis , 2015, Current Treatment Options in Cardiovascular Medicine.
[38] B. Prendergast,et al. A prospective, double-blind, randomized controlled trial of the angiotensin-converting enzyme inhibitor Ramipril In Aortic Stenosis (RIAS trial) , 2015, European heart journal cardiovascular Imaging.
[39] K. Alexander,et al. Futility, benefit, and transcatheter aortic valve replacement. , 2014, JACC. Cardiovascular interventions.
[40] K. Swedberg,et al. Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study). , 2014, The American journal of cardiology.
[41] A. Bogers,et al. Aortic stenosis in the elderly: disease prevalence and number of candidates for transcatheter aortic valve replacement: a meta-analysis and modeling study. , 2013, Journal of the American College of Cardiology.
[42] S. Saba,et al. Mechanistic Features Associated With Improvement in Mitral Regurgitation After Cardiac Resynchronization Therapy and Their Relation to Long-Term Patient Outcome , 2013, Circulation. Heart failure.
[43] M. Dweck,et al. Calcific aortic stenosis: a disease of the valve and the myocardium. , 2012, Journal of the American College of Cardiology.
[44] Benjamin R. Szwejkowski,et al. The impact of renin-angiotensin-aldosterone system blockade on heart failure outcomes and mortality in patients identified to have aortic regurgitation: a large population cohort study. , 2011, Journal of the American College of Cardiology.
[45] M. Keane,et al. Evidence of atrial functional mitral regurgitation due to atrial fibrillation: reversal with arrhythmia control. , 2011, Journal of the American College of Cardiology.
[46] K. Swedberg,et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy , 2011, European heart journal.
[47] M. Enriquez-Sarano,et al. Independent prognostic value of functional mitral regurgitation in patients with heart failure. A quantitative analysis of 1256 patients with ischaemic and non-ischaemic dilated cardiomyopathy , 2011, Heart.
[48] J. Junttila,et al. Respective Prevalence of the Different Carpentier Classes of Mitral Regurgitation: A Stepping Stone for Future Therapeutic Research and Development , 2011, Journal of cardiac surgery.
[49] Stuart J Pocock,et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. , 2011, The New England journal of medicine.
[50] P. Varadarajan,et al. Effect of beta-blocker therapy on survival in patients with severe aortic regurgitation results from a cohort of 756 patients. , 2009, Journal of the American College of Cardiology.
[51] W. Gaasch,et al. Left ventricular response to mitral regurgitation: implications for management. , 2008, Circulation.
[52] M. Gold,et al. REsynchronization reVErses Remodeling in Systolic left ventricular dysfunction (REVERSE) , 2008 .
[53] H. White,et al. A randomized trial of the aldosterone-receptor antagonist eplerenone in asymptomatic moderate-severe aortic stenosis. , 2008, American heart journal.
[54] H. Tsutsui. [Candesartan in heart failure: assessment of reduction in mortality and morbidity]. , 2007, Nihon rinsho. Japanese journal of clinical medicine.
[55] J. Gardin,et al. Burden of valvular heart diseases: a population-based study , 2006, The Lancet.
[56] C. Pappone,et al. Role of regional mechanical dyssynchrony as a determinant of functional mitral regurgitation in patients with left ventricular systolic dysfunction , 2006, Heart.
[57] A. Evangelista,et al. Long-term vasodilator therapy in patients with severe aortic regurgitation. , 2005, The New England journal of medicine.
[58] M. Enriquez-Sarano,et al. Heart Failure and Death After Myocardial Infarction in the Community: The Emerging Role of Mitral Regurgitation , 2005, Circulation.
[59] S. Solomon,et al. Mortality and Morbidity Reduction With Candesartan in Patients With Chronic Heart Failure and Left Ventricular Systolic Dysfunction: Results of the CHARM Low–Left Ventricular Ejection Fraction Trials , 2004, Circulation.
[60] R Alagesan,et al. Safety and efficacy of angiotensin-converting enzyme inhibitors in symptomatic severe aortic stenosis: Symptomatic Cardiac Obstruction-Pilot Study of Enalapril in Aortic Stenosis (SCOPE-AS). , 2004, American heart journal.
[61] M. Böhm,et al. Increased exercise ejection fraction and reversed remodeling after long‐term treatment with metoprolol in congestive heart failure: a randomized, stratified, double‐blind, placebo‐controlled trial in mild to moderate heart failure due to ischemic or idiopathic dilated cardiomyopathy , 2003, European journal of heart failure.
[62] E. Tuzcu,et al. Nitroprusside in critically ill patients with left ventricular dysfunction and aortic stenosis. , 2003, The New England journal of medicine.
[63] D. Delurgio,et al. Effect of Cardiac Resynchronization Therapy on Left Ventricular Size and Function in Chronic Heart Failure , 2003, Circulation.
[64] J. Gómez-Hospital,et al. Effect of carvedilol therapy on functional mitral regurgitation, ventricular remodeling, and contractility in patients with heart failure due to left ventricular systolic dysfunction. , 2002, Transplantation proceedings.
[65] B. Pitt,et al. The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure , 2000 .
[66] F. Ståhlberg,et al. Vasodilatation with felodipine in chronic asymptomatic aortic regurgitation. , 2000, American heart journal.
[67] B. Pitt,et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.
[68] Fach,et al. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) , 1999, The Lancet.
[69] W. Abraham,et al. Effects of carvedilol on left ventricular mass, chamber geometry, and mitral regurgitation in chronic heart failure. , 1999, The American journal of cardiology.
[70] CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial , 1999, The Lancet.
[71] T. Levine,et al. Effects of high-dose lisinopril-isosorbide dinitrate on severe mitral regurgitation and heart failure remodeling. , 1998, The American journal of cardiology.
[72] W. Rydlewska-sadowska,et al. Captopril or nifedipine? Comparison of rest and exercise acute effects and long-term therapy in chronic isolated asymptomatic moderate to severe aortic regurgitation. , 1998, The Journal of heart valve disease.
[73] W. Gaasch,et al. Vasoactive drugs in chronic regurgitant lesions of the mitral and aortic valves. , 1996, Journal of the American College of Cardiology.
[74] S. Rahimtoola,et al. Nifedipine in asymptomatic patients with severe aortic regurgitation and normal left ventricular function. , 1994, The New England journal of medicine.
[75] H. Schön. Hemodynamic and morphologic changes after long‐term angiotensin converting enzyme inhibition in patients with chronic valvular regurgitation , 1994, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.
[76] E. Murphy,et al. Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan's syndrome. , 1994, The New England journal of medicine.
[77] Salim Yusuf,et al. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.
[78] F. Tristani,et al. Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure , 1986 .
[79] J. Spann,et al. Differences in myocardial performance and load between patients with similar amounts of chronic aortic versus chronic mitral regurgitation. , 1984, Journal of the American College of Cardiology.
[80] B MAYNE,et al. On aortic regurgitation , 1953, Irish journal of medical science.
[81] G. Mancia,et al. Antihypertensive treatment with calcium channel blockers in patients with moderate or severe aortic stenosis: Relationship with all-cause mortality. , 2019, International journal of cardiology.
[82] P. Voisine,et al. Transcatheter Mitral-Valve Repair in Patients with Heart Failure. , 2019, The New England journal of medicine.
[83] M. Cheitlin. Independent prognostic value of functional mitral regurgitation in patients with heart failure. A quantitative analysis of 1256 patients with ischaemic and non-ischaemic dilated cardiomyopathy , 2012 .
[84] M. Cheitlin. Cardiac Resynchronization Induces Major Structural and Functional Reverse Remodeling in Patients With New York Heart Association Class I/II Heart Failure , 2011 .
[85] K. Swedberg,et al. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). , 1988, The American journal of cardiology.